Jupiter Neurosciences, Inc. announced on January 30, 2025, a strategic partnership with Zina Biopharmaceuticals, LLC. This collaboration will support all aspects of Jupiter’s upcoming Phase 2a clinical trial for Parkinson’s disease.
Under the agreement, Zina Biopharmaceuticals will provide comprehensive services, including clinical trial protocol design, pharmacokinetics and biomarker assessment, regulatory strategy, and trial site selection. This aims to accelerate the development timeline for JOTROL™.
Parkinson’s disease affects over 10 million people globally, with no disease-modifying treatments currently available. The global Parkinson’s therapeutics market is projected to exceed $14 billion by 2030, highlighting the significant unmet medical need Jupiter Neurosciences aims to address.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.